{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:08Z","timestamp":1787181908481,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Leading talent project of Hunan Provincial People's Hospital","award":["20230327-1012"],"award-info":[{"award-number":["20230327-1012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05105-x","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:14:56Z","timestamp":1779524096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatocellular carcinoma-cholangiocarcinoma collision tumor with excellent therapeutic response: a case report and literature review"],"prefix":"10.1007","volume":"17","author":[{"given":"Zengpeng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"5105_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.14218\/JCTH.2017.00076","volume":"6","author":"D Y\u0131lmaz","year":"2018","unstructured":"Y\u0131lmaz D. Incidental collision tumor of hepatocellular carcinoma and neuroendocrine carcinoma. J Clin Transl Hepatol. 2018;6:339.","journal-title":"J Clin Transl Hepatol"},{"key":"5105_CR2","first-page":"13129","volume":"10","author":"K-S Jeng","year":"2022","unstructured":"Jeng K-S, et al. Liver collision tumor of primary hepatocellular carcinoma and neuroendocrine carcinoma: A rare case report.World. J Clin Cases. 2022;10:13129.","journal-title":"J Clin Cases"},{"issue":"11","key":"5105_CR3","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/gut.2008.149062","volume":"57","author":"MA Silva","year":"2008","unstructured":"Silva MA, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57(11):1592\u20136.","journal-title":"Gut"},{"issue":"4","key":"5105_CR4","first-page":"647","volume":"25","author":"RA Allen","year":"1949","unstructured":"Allen RA, Lisa JR. Combined liver cell ahd bile duct carcinoma. Am J Pathol. 1949;25(4):647.","journal-title":"Am J Pathol"},{"key":"5105_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3904\/kjim.2007.22.4.283","volume":"22","author":"C Hong","year":"2007","unstructured":"Hong C, Kyun, et al. A case of combined hepatocellular-cholangiocarcinoma with underlying schistosomiasis. Korean J Intern Med. 2007;22:283.","journal-title":"Korean J Intern Med"},{"key":"5105_CR6","first-page":"e5871","volume":"12","author":"W Al Hamoudi","year":"2012","unstructured":"Al Hamoudi W, et al. Coincidental occurrence of hepatocellular carcinoma and cholangiocarcinoma (collision tumors) after liver transplantation: a case report. Hepatitis monthly. HCC. 2012;12:e5871.","journal-title":"Hepatitis Monthly HCC"},{"key":"5105_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/0046-8177(95)90084-5","volume":"26","author":"T Maeda","year":"1995","unstructured":"Maeda T, et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol. 1995;26:956\u201364.","journal-title":"Hum Pathol"},{"key":"5105_CR8","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jhep.2022.07.029","volume":"77","author":"N Rosenberg","year":"2022","unstructured":"Rosenberg N, et al. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. J Hepatol. 2022;77:1631\u201341.","journal-title":"J Hepatol"},{"key":"5105_CR9","doi-asserted-by":"publisher","DOI":"10.1159\/000549355","author":"J Li","year":"2026","unstructured":"Li J, Liang YB, Wang QB, Luo WL, Chen XM, Lakanga Y, Yang ZS, Zuo JX, Li YK, Li Z, Peng Y, Chen YB, Ke Y. Rechallenge with immune checkpoint inhibitors in patients with hepatocellular carcinoma: a narrative review. Liver Cancer. 2026. https:\/\/doi.org\/10.1159\/000549355","journal-title":"Liver Cancer"},{"key":"5105_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro B, et al. Advances in immunotherapy for hepatocellular carcinoma. Nat reviews Gastroenterol Hepatol. 2021;18:525\u201343.","journal-title":"Nat reviews Gastroenterol Hepatol"},{"key":"5105_CR11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3892\/or.2013.2290","volume":"29","author":"R Dhanasekaran","year":"2013","unstructured":"Dhanasekaran R, et al. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 2013;29:1259\u201367.","journal-title":"Oncol Rep"},{"key":"5105_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"5105_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690\u2013701.","journal-title":"Lancet Oncol"},{"key":"5105_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"D-Y Oh","year":"2024","unstructured":"Oh D-Y, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5105_CR15","doi-asserted-by":"publisher","first-page":"e001240","DOI":"10.1136\/jitc-2020-001240","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer. 2020;8:e001240.","journal-title":"J Immunother Cancer"},{"key":"5105_CR16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jhep.2021.01.035","volume":"74","author":"A Beaufr\u00e8re","year":"2021","unstructured":"Beaufr\u00e8re A, Julien C, Val\u00e9rie P. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol. 2021;74:1212\u201324.","journal-title":"J Hepatol"},{"key":"5105_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjsurg.2004.03.018","volume":"189","author":"K Koh","year":"2005","unstructured":"Koh K, Lee H et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120\u20135.","journal-title":"Am J Surg"},{"key":"5105_CR18","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2147\/JHC.S544589","volume":"12","author":"Q-B Wang","year":"2025","unstructured":"Wang Q-B, Luo W-L, et al. Tumor compression of the hepatic or portal vein predicts the presence of microvascular invasion and satellite nodules in hepatocellular carcinoma: a retrospective study. J Hepatocellular Carcinoma. 2025;12:2055\u201367.","journal-title":"J Hepatocellular Carcinoma"},{"key":"5105_CR19","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.2147\/JHC.S556306","volume":"25","author":"W-L Luo","year":"2025","unstructured":"Luo W-L, Wang Q-B, Li Y-K, et al. Impact of middle hepatic vein resection during hemihepatectomy on surgical outcomes and long-term prognosis in hepatocellular carcinoma: a retrospective study. J Hepatocellular Carcinoma. 2025;25:2681\u201392.","journal-title":"J Hepatocellular Carcinoma"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05105-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05105-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05105-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:53:14Z","timestamp":1787179994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05105-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5105"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05105-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving humans were approved by the Ethics Committee of Hunan Provincial People\u2019s Hospital\/The First Affliated Hospital of Hunan Normal University. The studies were conducted in accordance with the local legislation and institutional requirements. The patient gave written informed consent for their personal or clinical details along with any identifying images to be published in this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient has provided informed consent for the publication of his medical information. All authors, including Zengpeng Sun, Yutao Wang, Chuang Peng, Zhiguo Tan, have given their informed consent for the publication of this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1216"}}